For example, treatment with the anti-CD30 Ab drug conjugate Brentuximab Vedotin (SGN-35) in HL patients resulted in the binding of SGN-35 with HRS-derived CD30+ EVs and SGN-35/CD30+ EVs, not only killing the CD30+ tumor cells directly but also targeting CD30- cells in the TME, such as eosinophils and mast cells, resulting in severe damage to EV internalization [220]. Here, TNFRSF8 is linked to neoplasm.